UBT251
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
The United Bio-Technology (Hengqin) Co · Phase 3 · Active, not recruiting · Enrollment 600
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| UBT251 Injection 4.0 mg | n/r | n/r | n/r | n/r | n/r |
| UBT251 Injection 6.0 mg | n/r | n/r | n/r | n/r | n/r |
| UBT251 Injection Placebo 4.0 mg | n/r | n/r | n/r | n/r | n/r |
| UBT251 Injection Placebo 6.0 mg | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.